Sarepta's Duchenne gene therapy slows disease progression at three years

By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...
Investor's Business Daily on MSN

Sarepta pops on Elevidys data; but will it save the embattled gene therapy?

Sarepta stock jumped Monday after the company unveiled three-year test results for its embattled gene therapy, Elevidys.

Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases

In his CEO Commentary, Frederic Revah, Ph.D., underscores the dedication, expertise and successes of Genethon's 240 scientists and professional staff as they pursue new gene therapy treatments for ...
The American Journal of Managed Care

Developments in Muscular Dystrophy Gene Therapy

Emma Ciafaloni, MD, FAAN, dives into the latest developments in gene therapy for muscular dystrophies, focusing on Duchenne muscular dystrophy, and discusses challenges, genetic causes, and the ...

Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...
InvestorsHub on MSN

Sarepta posts encouraging three-year data for Duchenne gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) released three-year follow-up results from its EMBARK study, showing that its gene ...
Labroots

A New Approach in Gene Therapy for Muscular Dystrophy

Scientists have created a new gene therapy for Duchenne muscular dystrophy (DMD) that may not only help stop the disease in DMD patients, but might also help restore their damaged muscles in the ...
BioSpace

Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
WLWT

FDA expands approval of first gene therapy for rare form of muscular dystrophy

The Muscular Dystrophy Association trusts the decision of the FDA, which weighs the risks and benefits of the drug The Muscular Dystrophy Association trusts the decision of the FDA, which weighs the ...
New Atlas

Muscular dystrophy-reversing gene therapy: Human trials in 2 years

A new gene therapy for Duchenne muscular dystrophy (DMD) has shown promise in not only slowing the progression of the disease but potentially even reversing the muscle damage, with human trials set to ...
Yahoo

Second patient death reported with gene therapy for muscular dystrophy

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the ...
MarketWatch

Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Patients Ages 4 and Above

The MarketWatch News Department was not involved in the creation of this content. Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular ...